IPP Bureau

NIH grants in-principle accreditation to Advanced Enzymes supplements
NIH grants in-principle accreditation to Advanced Enzymes supplements

By IPP Bureau - October 20, 2021

The panel concurred that these supplements resolved post-Covid-19 fatigue and muscle weakness

AstraZeneca India opens clinical data and insights division
AstraZeneca India opens clinical data and insights division

By IPP Bureau - October 20, 2021

The division is expected to grow to over a 100-member strong team by 2022

Trivitron partners with Diagon-Vanguard to launch its coagulation range in India
Trivitron partners with Diagon-Vanguard to launch its coagulation range in India

By IPP Bureau - October 20, 2021

The new products include the COAG Line automated, semi-automated and POC systems manufactured by Diagon Hungary

Domestic growth to the fore as US weakness persists: ICICI Direct
Domestic growth to the fore as US weakness persists: ICICI Direct

By IPP Bureau - October 19, 2021

ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report

U.S. FDA authorises new saliva sample collection for Covid-19
U.S. FDA authorises new saliva sample collection for Covid-19

By IPP Bureau - October 19, 2021

The Amplitude Solution gives laboratories the ability to scale Covid-19 PCR testing and process up to 8,000 samples a day

Pharma exports continue to climb in H1FY22
Pharma exports continue to climb in H1FY22

By IPP Bureau - October 19, 2021

Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.

Alcon announces launch of AcrySof IQ Vivity in India,
Alcon announces launch of AcrySof IQ Vivity in India,

By IPP Bureau - October 19, 2021

It is the first presbyopia-correcting lens implant for cataract surgery

Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules
Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules

By IPP Bureau - October 19, 2021

The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg

MSN Labs launches drug for diabetes management
MSN Labs launches drug for diabetes management

By IPP Bureau - October 19, 2021

The company claims that its Empagliflozin tablets are the most affordable in India

Vertex’s stem cell therapy for Type 1 diabetes reduced daily insulin requirement by 91 %
Vertex’s stem cell therapy for Type 1 diabetes reduced daily insulin requirement by 91 %

By IPP Bureau - October 19, 2021

The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit

Luke Coutinho launches e-commerce venture YouCareLifestyle
Luke Coutinho launches e-commerce venture YouCareLifestyle

By IPP Bureau - October 19, 2021

The platform will be a curated marketplace for sustainable-driven products by small-medium entrepreneurs and will encourage an autonomous marketplace

AstraZeneca ties up with Rajiv Gandhi Cancer Institute to treat patients with Chronic Lymphocytic Leukemia
AstraZeneca ties up with Rajiv Gandhi Cancer Institute to treat patients with Chronic Lymphocytic Leukemia

By IPP Bureau - October 19, 2021

Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region

WHO to take call on Covaxin's EUL on October 26th
WHO to take call on Covaxin's EUL on October 26th

By IPP Bureau - October 18, 2021

The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17

U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer
U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer

By IPP Bureau - October 18, 2021

Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting

Imfinzi plus tremelimumab significantly improved overall survival in liver cancer
Imfinzi plus tremelimumab significantly improved overall survival in liver cancer

By IPP Bureau - October 18, 2021

The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib

Latest Stories

Interviews

Packaging